Loading search results
Sponsor study identifier
Secondary identifiers
observational
4,893
2 countries
6
Study Start
May 25, 2010
Actual (reported)Primary Completion
December 31, 2015
Actual (reported)Study Completion
May 21, 2020
Actual (reported)Burkitt lymphoma (BL) is an aggressive monoclonal B-cell malignancy that is rare (sporadic) worldwide, but is 100-fold more common (endemic) in equatorial Africa, particularly among children. Epstein-Barr virus (EBV) and malaria are epidemiologically linked to endemic BL in epidemiologic studies, but questions remain about role of EBV variants and the evidence for association with malaria is weak. EBV is ubiquitous, yet only few children develop BL, possibly because only a few EBV variants are pathogenically relevant. The association of BL with malaria is based on ecologic and non-comparative clinical studies. Two case-control studies have reported significant association of high anti-malarial antibodies with BL (OR=5\_ among children in Uganda and in Malawi, but selection bias (cases and controls came from dissimilar geographical areas) and reverse causality bias were limitations. Three studies were conducted in the 1960s and 70s to test association of carriage of malaria-resistance gene with BL, two of which reported a significant or marginal inverse association. These pioneering studies were small (240 cases all together) and looked at one polymorphism in one gene (sickle cell gene). Improvements in technologies to characterize genetic variation allow the EBV and malaria hypotheses to be examined with greater power by looking at genetic variation across multiple genes. Epidemiology of Burkitt lymphoma in East African children and minors (EMBLEM) is a case-control study of 1500 BL cases and 3000 age-, sex- and residence-frequency matched controls we are proposing to conduct in East Africa. The study will enroll cases at four hospitals in four regions in East Africa, where malaria transmission is holoendemic and year round. The controls will be enrolled from general population attendees at Health Center II (HC-II) units where the cases originated. The primary study objectives are: 1) to test the hypothesis that genetic resistance to malaria is associated with a lower risk of BL, and 2) to use genome-wide association methods to discover genetic variation that may be associated with decreased or increased risk of BL. Because genetic variation conveys no information on actual exposure to malaria or EBV, in secondary analyses, we will use empiric epidemiological questionnaire and laboratory methods: a) to measure exposure to malaria and its association with BL, and b) to measure EBV variants and their association with BL. To examine issues related to bias and to obtain data to correct for deviations, we will also enroll 2250 population controls from 5% of the villages to obtain population distribution of key exposures variables. This data will be used to reweight the distribution in HC-II controls back to the general population. ...
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 21, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 25, 2010
Actual (reported)September 4, 2010
Actual (reported)September 8, 2010
Actual (reported)December 31, 2015
Actual (reported)May 21, 2020
Actual (reported)Burkitts Lymphoma
Newly diagnosed case of BL confirmed by histology or cytology.
At enrollment
Malaria
At enrollment
Children from East Africa diagnosed with BL
Matched controls from the local health clinics
Matched controls from the geographic region
Residents of Northern Uganda, Western Kenya, and Northern Tanzania.
Bugando Medical Center
Mwanza, Tanzania
Shirati Health, Educational, and Development Foundation
Shirati, Tanzania
St.Mary's Hospital Lacor
Gulu, Uganda
Kuluva Hospital (Arua)
Kampala, Uganda
Homabay District Hospital
Nyanza, Uganda
Webuye District Hospital
Webuye, Uganda
BURKITT D. A sarcoma involving the jaws in African children. Br J Surg. 1958 Nov;46(197):218-23. doi: 10.1002/bjs.18004619704. No abstract available.
Levine PH, Connelly RR, McKay FW. Burkitt's lymphoma in the USA: cases reported to the American Burkitt Lymphoma Registry compared with population-based incidence and mortality data. IARC Sci Publ. 1985;(60):217-24.
Burkitt D. Burkitt's lymphoma outside the known endemic areas of Africa and New Guinea. Int J Cancer. 1967 Nov 15;2(6):562-5. doi: 10.1002/ijc.2910020603. No abstract available.
Sam M Mbulaiteye, M.D.
National Cancer Institute (NCI)
4,893 participants (actual enrollment reported by the registry).
First Submitted
September 4, 2010
First Posted
September 8, 2010
Study Start
May 25, 2010
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
December 31, 2015
Actual (reported)Study Completion
May 21, 2020
Actual (reported)Last Updated
May 22, 2020
Record last verified: 2020-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: